COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: TED  ROSS
Organization: UNIVERSITY OF GEORGIA
Fiscal Year: 2022
Award: $61,062
Funding agency: National Institute of Allergy and Infectious Diseases

The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to evaluate antibody responses to SARS-CoV-2 virus in high risk  populations including health workers, first responders, frontline worker (e.g. grocery store employees) and disproportionately affected minorities.  The goal of the study is to determine the durability of antibody titers following COVID infection and to identify correlates of antibody-mediated protection from re-infection in COVID survivors.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Ab-mediated immunity><Ab-mediated protection><Affect><Antibody Response><Antibody immunity><Antibody protection><Antibody titer measurement><Antibody-mediated protection><COVID><COVID survivors><COVID-19 infection survivors><COVID-19 survivors><COVID-19 virus><COVID19 virus><CoV disease><CoV-2><CoV2><Employee><Foundations><Front line employee><Front line person><Front line personnel><Front line staff><Front line worker><Frontline employee><Frontline person><Frontline personnel><Frontline staff><Frontline worker><Goals><Health><Immune response><Immunological response><Infection><Minority><NCI Organization><National Cancer Institute><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 survivors><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Universities><Virus><Wuhan coronavirus><antibody titering><antibody-mediated immunity><corona virus disease><coronavirus disease><coronavirus disease 2019 virus><coronavirus disease-19 virus><first responder><hCoV19><high risk group><high risk population><host response><immune system response><immunoresponse><nCoV2><survive COVID-19><survive SARS-CoV-2>